Entrada Therapeutics, Inc. (NASDAQ:TRDA – Get Free Report) major shareholder Bioventures 2018 L.P. Mpm sold 38,922 shares of the company’s stock in a transaction that occurred on Thursday, August 27th. The shares were sold at an average price of $7.20, for a total value of $280,238.40. Following the completion of the transaction, the insider directly owned 4,279,426 shares of the company’s stock, valued at approximately $30,811,867.20. This represents a 0.90% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Major shareholders that own more than 10% of a company’s stock are required to disclose their transactions with the SEC.
Bioventures 2018 L.P. Mpm also recently made the following trade(s):
- On Monday, August 31st, Bioventures 2018 L.P. Mpm sold 44,259 shares of Entrada Therapeutics stock. The shares were sold at an average price of $6.99, for a total value of $309,370.41.
- On Friday, August 28th, Bioventures 2018 L.P. Mpm sold 3,733 shares of Entrada Therapeutics stock. The stock was sold at an average price of $7.01, for a total value of $26,168.33.
Entrada Therapeutics Trading Up 0.7%
TRDA stock opened at $7.05 on Tuesday. The stock’s fifty day simple moving average is $7.08 and its two-hundred day simple moving average is $9.28. Entrada Therapeutics, Inc. has a 1-year low of $5.02 and a 1-year high of $16.45. The stock has a market cap of $274.53 million, a P/E ratio of -1.78 and a beta of -0.26.
Institutional Investors Weigh In On Entrada Therapeutics
Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. State of Wyoming bought a new stake in Entrada Therapeutics in the 2nd quarter valued at about $37,000. Russell Investments Group Ltd. boosted its position in Entrada Therapeutics by 72.7% during the third quarter. Russell Investments Group Ltd. now owns 8,808 shares of the company’s stock worth $51,000 after purchasing an additional 3,707 shares during the period. Occudo Quantitative Strategies LP purchased a new position in shares of Entrada Therapeutics in the second quarter worth about $68,000. Jain Global LLC purchased a new position in shares of Entrada Therapeutics in the third quarter worth about $69,000. Finally, IHT Wealth Management LLC bought a new stake in shares of Entrada Therapeutics in the second quarter valued at approximately $72,000. 86.39% of the stock is currently owned by institutional investors.
Wall Street Analysts Forecast Growth
Several analysts have commented on the stock. Guggenheim lowered their price objective on shares of Entrada Therapeutics from $20.00 to $17.00 and set a “buy” rating on the stock in a research report on Monday, June 8th. HC Wainwright downgraded shares of Entrada Therapeutics from a “buy” rating to a “neutral” rating in a research report on Friday, May 8th. Weiss Ratings lowered shares of Entrada Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Thursday, August 13th. Finally, Roth Capital reiterated a “buy” rating and issued a $11.00 price objective on shares of Entrada Therapeutics in a research note on Wednesday, August 12th. Four investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, Entrada Therapeutics presently has an average rating of “Moderate Buy” and an average price target of $17.75.
View Our Latest Analysis on Entrada Therapeutics
Entrada Therapeutics Company Profile
Entrada Therapeutics (NASDAQ: TRDA) is a clinical-stage biotechnology company focused on enabling the development of protein-based therapeutics that can cross cell membranes and engage intracellular targets. Using its proprietary cell-penetrating miniature protein (CPMP) platform and intracellular targeting of proteins (iTOP) delivery technology, Entrada aims to expand the range of diseases addressable by large-molecule drugs.
The company’s pipeline includes programs in rare and serious diseases where conventional biologics have limited intracellular activity.
Featured Stories
- Five stocks we like better than Entrada Therapeutics
- Securing AI: 5 Most-Upgraded Stocks From the Q2 Reporting Season
- Insiders Are Betting Big on These 3 Healthcare Stocks
- 3 Stocks for Investors Who Still Believe Cash Is King
- Dollar General and Dollar Tree Are Recovering, But Not for the Same Reason
Receive News & Ratings for Entrada Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Entrada Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
